The model was found to be predictive and may help identify patients with multiple myeloma at a high risk of early disease progression.
Progression-free survival (PFS) in multiple myeloma (MM) has improved in recent years, but the disease remains incurable, and some patients progress quickly despite advances in MM management. A study published in Hematology analyzed data on factors of MM progression within a year of diagnosis to form a risk prediction model for early progression in patients with newly diagnosed multiple myeloma (NDMM).
“In the past decade, due to the continuous maturation of autologous stem cell transplantation (ASCT) technology and the continuous progress of symptomatic support treatment, such as anti-rejection and anti-infection treatments after transplantation, the survival rate of MM patients has been significantly improved,” the authors wrote. Overall survival (OS) and PFS have both increased, but some patients with NDMM progress quickly, even with treatment.
The retrospective analysis aimed to produce a predictive model for early progression based on basic clinical characteristics and test indicators of patients diagnosed with MM in the Department of Hematology at The People's Hospital of Shangrao City in Jiangxi Province, China, between January 2015 and January 2020.
A total of 108 patients with NDMM were included in the study, which included univariate and multivariate logistic regression analyses to determine the factors contributing to early MM progression. Early progression was defined as disease progression within 1 year in patients with NDMM.
The independent variables assessed for the model included age, sex, clinical stage (Durie-Salmon stage, International Staging System stage), the proportion of plasma cells in bone marrow, treatment regimens, neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH), serum corrected calcium, blood β2-microglobulin (β2-MG), serum creatinine (Scr), and hepatitis B surface antigen (HBsAg). Disease status was the sole dependent variable.
The analysis showed that a treatment regimen containing at least 2 agents reduced the risk of progression (odds ratio [OR], 0.226; 95% CI, 0.068-0.753; P < .05). An increase in LDH levels and an increase in serum corrected calcium levels were both found to be risk indicators for disease progression (OR, 3.452; 95% CI, 1.101-10.826; P < .05; and OR, 4.466; 95% CI, 1.346-14.811; P < .05, respectively).
The established prediction model is as follows:
X = −2.042 – 1.489 × treatment regimen (including at least 2 targeted drugs is 1, otherwise 0) + 1.239 × LDH level (U/L, increased is 1, normal is 0) + 1.496 × serum corrected calcium level (mmol/L, increased is 1, normal is 0)
The model’s accuracy was evaluated with a receiver operating characteristic curve analysis, which showed that the model performed well.
Although the study size was small and it was single center in nature, the findings add to current knowledge of MM risk factors. While further research is necessary to externally validate the model, it was found to be predictive and may be used as a reference for clinicians as they individualize treatment plans for their patients.
“Our prediction model shows that MM patients with high levels of LDH and high blood calcium are more likely to have early disease progression,” the authors concluded. “The use of targeted drugs can reduce the risk of early disease progression, help patients obtain better treatment effects, create opportunities for maintenance treatment, hematopoietic stem cell transplantation and CAR-T therapy, and bring longer PFS times to patients.”
Reference
Wei H, Sun Z, Ye X, Yu J, Ye Y, Wang Z. Establishment of a prediction model for disease progression within one year in newly diagnosed multiple myeloma patients. Hematology. Published online May 26, 2022. doi:10.1080/16078454.2022.2067940
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
Fracture Risk Lowest for Alendronate, Pamidronate Use During MM Treatment
March 21st 2024In this analysis, 3 bisphosphonates (alendronate, pamidronate, and zoledronic acid) and 1 RANK ligand inhibitor (denosumab) were evaluated for their effectiveness at preventing osteoclasts from facilitating jaw degradation and reducing vertebral fracture risk among patients being treated for multiple myeloma.
Read More
Teclistamab Approved for Biweekly Dosing in R/R Multiple Myeloma
February 23rd 2024The bispecific antibody is used to treat patients with relapsed or refractory multiple myeloma (R/R MM) who have achieved and maintained a complete response for at least 6 months; this approval allows a dosing frequency of 1.5 mg/kg every 2 weeks.
Read More
Daratumumab-Based Regimen Potential Promising Bridging Therapy for RRMM
February 15th 2024The combination of daratumumab and immumodulatory therapy was evaluated among patients with relapsed/refractory multiple myeloma (RRMM) who have failed prior treatment with immunomodulatory agents, proteasome inhibitors, and daratumumab as monotherapy or in combination.
Read More
Disability Degree, Home Health Use May Signal Need for Patient Support in MM
February 7th 2024Clinical investigators evaluated the impact of home health services on disability status and receipt of treatment among adults 66 years and older with a new diagnosis of multiple myeloma (MM).
Read More